In conclusion, this study has demonstrated that Shenfu injection can inhibit ferroptosis in yang-deficient CHF through the activation of the Akt/GSK-3β/Nrf2 pathway, revealing new avenues for the development of clinical novel therapies for the treatment of yang-deficient CHF. This evidence concerns the gene AKT1 and congestive heart failure.